Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (NCT05761171) | Children's Oncology Group | 2024-01-08 |
Track Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged automatically
Every clearance here is in the API, with alerts when new ones post.